Protara is a development-stage, clinical biopharmaceutical company focused on bringing life-saving therapies to patients who suffer from rare diseases. The Company's core strategy is to identify and acquire or license overlooked or undervalued products or product candidates and modernize or optimize development programs for these assets. Protara’s current development programs focus on therapeutics for rare structural disorders as well as rare hepatology/gastrointestinal and metabolic disorders. TARA-002, Protara's lead program, is a follow-on biologic of the immunotherapy OK-432 (marketed as Picibanil in Japan and Taiwan by Chugai Pharmaceutical). The Company is pursuing two separate indications for TARA-002: Lymphatic Malformations (LMs) and Non-Muscle Invasive Bladder Cancel (NMIBC).